SAB Biotherapeutics (SABS) Preferred Stock Liabilities (2021)
SAB Biotherapeutics' (SABS) quarterly Preferred Stock Liabilities came in at $116.2 million in Q3 2021, up 13.66% on a QoQ basis from $102.2 million in Q2 2021.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Preferred Stock Liabilities (2021) Analysis & Trends
SAB Biotherapeutics (SABS) has 1 years of Preferred Stock Liabilities data on file, last reported at $116.2 million in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | SAB Biotherapeutics | 296.68 Mn | 296.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 116.15 Mn |
| Jun 30, 2021 | 102.19 Mn |
| Mar 31, 2021 | 104.39 Mn |